Acute cardiac care & resuscitation
Inotrope versus placebo therapy in cardiogenic shock: Rationale and study design of the CAPITAL DOREMI2 trial
Study context
- Population
- Patients with SCAI class C or D cardiogenic shock, initial resuscitationplanned
- Participants
- 346 patients
- Planned comparison
- Single-agent inotrope vs placebo
- Primary endpoint
- Composite of all-cause in-hospital death and, during the 12-hour intervention period, any of: sustained hypotension or high dose vasopressor requirements, lactate >3.5 mmol/L at 6 hours or thereafter, need for mechanical circulatory support, arrhythmia leading to emergent electrical cardioversion, resuscitated cardiac arrest
Methodological detailsrationale and study design, multicentre, double-blind, placebo-controlled, 1:1 randomisation, After the 12-hour period, open-label therapies at the treating team's discretion, Followed for the duration of hospitalisation; secondary outcomes assessed at discharge
- Rationale and study design
- Multicentre
- Double-blind
- Placebo-controlled
- 1:1 randomisation
- After the 12-hour period, open-label therapies at the treating team's discretion
- Followed for the duration of hospitalisation; secondary outcomes assessed at discharge
No results yet. This paper sets out the design of a trial; its results are to come.
Original publication
Inotrope versus placebo therapy in cardiogenic shock: Rationale and study design of the CAPITAL DOREMI2 trial. Am Heart J. Published 23 April 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →